Cargando…
Patient-reported outcomes in adoptive cell-therapy trials: mind the gap
Adoptive cell therapies (ACT) have demonstrated promise in the treatment of patients with cancer, leading to long-lasting responses and, in some cases, even cure. Technological advances have brought these individualized therapies closer to reality, establishing them as credible therapeutic option. H...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743398/ https://www.ncbi.nlm.nih.gov/pubmed/36600604 http://dx.doi.org/10.1136/jitc-2022-006082 |
_version_ | 1784848718319583232 |
---|---|
author | Ghisoni, Eleonora Morotti, Matteo Colomer-Lahiguera, Sara Eicher, Manuela Coukos, George Trueb, Lionel Di Maio, Massimo |
author_facet | Ghisoni, Eleonora Morotti, Matteo Colomer-Lahiguera, Sara Eicher, Manuela Coukos, George Trueb, Lionel Di Maio, Massimo |
author_sort | Ghisoni, Eleonora |
collection | PubMed |
description | Adoptive cell therapies (ACT) have demonstrated promise in the treatment of patients with cancer, leading to long-lasting responses and, in some cases, even cure. Technological advances have brought these individualized therapies closer to reality, establishing them as credible therapeutic option. However, to date, few efforts have been made to understand patients' experience during ACT trials. Patient-reported outcomes (PROs) and patient-reported outcome measures (PROMs), which are instruments used to report PROs, are increasingly being used in oncology to capture patients’ perspective, provide real-world data on treatment safety, and support decision-making processes, such as health economic decisions. Due to the inherent complexity of ACT, the inclusion of PROMs in this field remains limited. In this commentary, we discuss the benefit of capturing PROs in ACT trials, the challenges of PROM administration and collection, and we propose simple and actionable recommendations to promote their adoption in ACT trials. |
format | Online Article Text |
id | pubmed-9743398 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-97433982022-12-13 Patient-reported outcomes in adoptive cell-therapy trials: mind the gap Ghisoni, Eleonora Morotti, Matteo Colomer-Lahiguera, Sara Eicher, Manuela Coukos, George Trueb, Lionel Di Maio, Massimo J Immunother Cancer Commentary Adoptive cell therapies (ACT) have demonstrated promise in the treatment of patients with cancer, leading to long-lasting responses and, in some cases, even cure. Technological advances have brought these individualized therapies closer to reality, establishing them as credible therapeutic option. However, to date, few efforts have been made to understand patients' experience during ACT trials. Patient-reported outcomes (PROs) and patient-reported outcome measures (PROMs), which are instruments used to report PROs, are increasingly being used in oncology to capture patients’ perspective, provide real-world data on treatment safety, and support decision-making processes, such as health economic decisions. Due to the inherent complexity of ACT, the inclusion of PROMs in this field remains limited. In this commentary, we discuss the benefit of capturing PROs in ACT trials, the challenges of PROM administration and collection, and we propose simple and actionable recommendations to promote their adoption in ACT trials. BMJ Publishing Group 2022-12-09 /pmc/articles/PMC9743398/ /pubmed/36600604 http://dx.doi.org/10.1136/jitc-2022-006082 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Commentary Ghisoni, Eleonora Morotti, Matteo Colomer-Lahiguera, Sara Eicher, Manuela Coukos, George Trueb, Lionel Di Maio, Massimo Patient-reported outcomes in adoptive cell-therapy trials: mind the gap |
title | Patient-reported outcomes in adoptive cell-therapy trials: mind the gap |
title_full | Patient-reported outcomes in adoptive cell-therapy trials: mind the gap |
title_fullStr | Patient-reported outcomes in adoptive cell-therapy trials: mind the gap |
title_full_unstemmed | Patient-reported outcomes in adoptive cell-therapy trials: mind the gap |
title_short | Patient-reported outcomes in adoptive cell-therapy trials: mind the gap |
title_sort | patient-reported outcomes in adoptive cell-therapy trials: mind the gap |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743398/ https://www.ncbi.nlm.nih.gov/pubmed/36600604 http://dx.doi.org/10.1136/jitc-2022-006082 |
work_keys_str_mv | AT ghisonieleonora patientreportedoutcomesinadoptivecelltherapytrialsmindthegap AT morottimatteo patientreportedoutcomesinadoptivecelltherapytrialsmindthegap AT colomerlahiguerasara patientreportedoutcomesinadoptivecelltherapytrialsmindthegap AT eichermanuela patientreportedoutcomesinadoptivecelltherapytrialsmindthegap AT coukosgeorge patientreportedoutcomesinadoptivecelltherapytrialsmindthegap AT trueblionel patientreportedoutcomesinadoptivecelltherapytrialsmindthegap AT dimaiomassimo patientreportedoutcomesinadoptivecelltherapytrialsmindthegap |